PO72 | CATHETER-RELATED THROMBOSIS VS FIBROBLASTIC SLEEVE. INCIDENCE AND IMPACT IN ONCOLOGICAL AND HEMATOLOGICAL PATIENTS WITH PERIPHERALLY INSERTED CENTRAL CATHETER

Introduction. Oncohematological patients often have peripherally inserted central venous catheters (PICC). Associated complications are venous thrombosis or fibroblastic sleeve. The correct discrimination between the two is important, as they are similar by ultrasound, but their management is different, with anticoagulant therapy needed only for thrombosis. Materials and Methods. In a cohort of 45 consecutive oncological patients with PICC, we evaluated the incidence of catheter-related thrombosis (CRT) versus fibroblastic sleeve (FS) at 7-10 and 28-30 days. The type of oncological disease was also assessed. Results. FS was identified in 11 patients (24.4%): 6 at 7-10 days (13.3%) and 5 at 28-30 days (11.1%); 5 patients (45.6%) had gastrointestinal cancer, 2 (18.1%) had respiratory tract cancer and 4 had breast cancer (36.3%). CRT was identified in 5 patients (11.1%): 3 at 7-10 days (60.0%) and 2 at 28-30 days (40.0%); 3 patients had gastrointestinal cancer (60.0%), 1 (20%) gynecological cancer and 1 (20%) onco-hematological disease. Three thromboses were asymptomatic (60.0%). The relationship between vein diameter and development of fibroblastic sleeve/thrombosis was not significant (p=0.069), whereas the relationship between the timing of the complication and the platelets count (OR 1.03, 95% CI: 1.01 – 1.08) was statistically significant (p=0.039). Discussion. FS is frequent (24.4%), however mainly asymptomatic, in cancer patients. CRT is less frequent (11.1%), but it carries significant morbidity. Discrimination between FS and CRT is clinically relevant in order to avoid unnecessary anticoagulation and its potentially serious side effects. References 1. G. Passaro, M. Pittiruti and A. La Greca. The fibroblastic sleeve, the neglected complication of venous access devices: a narrative review. JVA 2020; 2. Trezza C, Califano C, Iovino V, D'Ambrosio C, Grimaldi G, Pittiruti M. Incidence of fibroblastic sleeve and of catheter-related venous thrombosis in peripherally inserted central catheters: A prospective study on oncological and hematological patients. J Vasc Access. 2021 May;22(3):444-449.

Authors

Institutions

Publication Details

Journal
DOAJ (DOAJ: Directory of Open Access Journals)
Published
2026-04-01
Primary Topic
Central Venous Catheters and Hemodialysis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PO72 | CATHETER-RELATED THROMBOSIS VS FIBROBLASTIC SLEEVE. INCIDENCE AND IMPACT IN ONCOLOGICAL AND HEMATOLOGICAL PATIENTS WITH PERIPHERALLY INSERTED CENTRAL CATHETER

Raffaele Natale
DOAJ (DOAJ: Directory of Open Access Journals)
Central Venous Catheters and Hemodialysis
article

PO72 | CATHETER-RELATED THROMBOSIS VS FIBROBLASTIC SLEEVE. INCIDENCE AND IMPACT IN ONCOLOGICAL AND HEMATOLOGICAL PATIENTS WITH PERIPHERALLY INSERTED CENTRAL CATHETER

Raffaele Natale
article en

Abstract

Introduction. Oncohematological patients often have peripherally inserted central venous catheters (PICC). Associated complications are venous thrombosis or fibroblastic sleeve. The correct discrimination between the two is important, as they are similar by ultrasound, but their management is different, with anticoagulant therapy needed only for thrombosis. Materials and Methods. In a cohort of 45 consecutive oncological patients with PICC, we evaluated the incidence of catheter-related thrombosis (CRT) versus fibroblastic sleeve (FS) at 7-10 and 28-30 days. The type of oncological disease was also assessed. Results. FS was identified in 11 patients (24.4%): 6 at 7-10 days (13.3%) and 5 at 28-30 days (11.1%); 5 patients (45.6%) had gastrointestinal cancer, 2 (18.1%) had respiratory tract cancer and 4 had breast cancer (36.3%). CRT was identified in 5 patients (11.1%): 3 at 7-10 days (60.0%) and 2 at 28-30 days (40.0%); 3 patients had gastrointestinal cancer (60.0%), 1 (20%) gynecological cancer and 1 (20%) onco-hematological disease. Three thromboses were asymptomatic (60.0%). The relationship between vein diameter and development of fibroblastic sleeve/thrombosis was not significant (p=0.069), whereas the relationship between the timing of the complication and the platelets count (OR 1.03, 95% CI: 1.01 – 1.08) was statistically significant (p=0.039). Discussion. FS is frequent (24.4%), however mainly asymptomatic, in cancer patients. CRT is less frequent (11.1%), but it carries significant morbidity. Discrimination between FS and CRT is clinically relevant in order to avoid unnecessary anticoagulation and its potentially serious side effects. References 1. G. Passaro, M. Pittiruti and A. La Greca. The fibroblastic sleeve, the neglected complication of venous access devices: a narrative review. JVA 2020; 2. Trezza C, Califano C, Iovino V, D'Ambrosio C, Grimaldi G, Pittiruti M. Incidence of fibroblastic sleeve and of catheter-related venous thrombosis in peripherally inserted central catheters: A prospective study on oncological and hematological patients. J Vasc Access. 2021 May;22(3):444-449.

DOAJ (DOAJ: Directory of Open Access Journals)
Federico II University Hospital (IT)
Peace, Justice and strong institutions
Openalex Percentile: Top 23%
Central Venous Catheters and Hemodialysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.